The Efficacy of Inosine Pranobex in Preventing the Acquired Immunodeficiency Syndrome in Patients with Human Immunodeficiency Virus Infection

Abstract

We performed a randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of inosine pranobex (isoprinosine) in the treatment of patients with human immunodeficiency virus (HIV) infection but without manifest acquired immunodeficiency syndrome (AIDS). A total of 866 patients were enrolled in 21 centers in Denmark and Sweden. The patients were stratified in three groups according to their CD4+ cell count and randomly assigned to receive either inosine pranobex (1 g three times a day) (n = 429) or matching placebo (n = 437) for 24 weeks.